BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34730200)

  • 1. High HBXIP expression is related to poor prognosis in HCC by extensive database interrogation.
    Guo ZY; Jiang LP; Zhu ZT
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6196-6207. PubMed ID: 34730200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
    Guo ZY; Zhu ZT
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
    Jiang W; Wu T; Shi X; Xu J
    Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
    Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
    Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 7. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Xu H; Xiong C; Chen Y; Zhang C; Bai D
    Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Komatsu H; Iguchi T; Masuda T; Hirata H; Ueda M; Kidogami S; Ogawa Y; Sato K; Hu Q; Nambara S; Saito T; Sakimura S; Uchi R; Ito S; Eguchi H; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
    Ann Surg Oncol; 2017 Mar; 24(3):850-859. PubMed ID: 27770342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
    Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
    Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
    Wang Y; Li N; Che S; Jin T; Piao J; Liu S; Lin Z
    Tumour Biol; 2017 Jul; 39(7):1010428317709675. PubMed ID: 28718367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.
    Sohn BH; Shim JJ; Kim SB; Jang KY; Kim SM; Kim JH; Hwang JE; Jang HJ; Lee HS; Kim SC; Jeong W; Kim SS; Park ES; Heo J; Kim YJ; Kim DG; Leem SH; Kaseb A; Hassan MM; Cha M; Chu IS; Johnson RL; Park YY; Lee JS
    Clin Cancer Res; 2016 Mar; 22(5):1256-64. PubMed ID: 26459179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report.
    Lü Y; Zhang J; Li L; Li S; Yang Z
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31990034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
    Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
    Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
    Li X; Lin J; Pan Y; Cui P; Xia J
    Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
    [No Abstract]   [Full Text] [Related]  

  • 18. Establishment of a Nomogram by Integrating Molecular Markers and Tumor-Node-Metastasis Staging System for Predicting the Prognosis of Hepatocellular Carcinoma.
    Huang XT; Chen LH; Huang CS; Li JH; Cai JP; Chen W; Yin XY
    Dig Surg; 2019; 36(5):426-432. PubMed ID: 30481744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.
    Zeng Z; Jiang X; Pan Z; Zhou R; Lin Z; Tang Y; Cui Y; Zhang E; Cao Z
    Aging (Albany NY); 2021 Oct; 13(19):22802-22829. PubMed ID: 34607313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of WNT family gene expression in hepatitis B virus‑related hepatocellular carcinoma.
    Han Q; Wang X; Liao X; Han C; Yu T; Yang C; Li G; Han B; Huang K; Zhu G; Liu Z; Zhou X; Su H; Shang L; Gong Y; Song X; Peng T; Ye X
    Oncol Rep; 2019 Sep; 42(3):895-910. PubMed ID: 31322232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.